mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Von Heyde, Silvia Der ^a,b   Wagner, Steve ^c   Czerny, Alexander ^a   Nietert, Manuel ^a   Ludewig, Fabian ^d   Salinas Riester, Gabriela ^d   Arlt, Dorit ^c   Beißbarth, Tim ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b IndivuTest GmbH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; CYCLOOXYGENASE 2; CYTOCHROME P450 1A2; DYSADHERIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 8; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SOMATOMEDIN BINDING PROTEIN 3; TRASTUZUMAB; ANTINEOPLASTIC AGENT; CAV1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

AFF3 GENE; ALPP GENE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CALCOCO1 GENE; CANCER RESISTANCE; CAV1 GENE; CLDN1 GENE; COLEC12 GENE; CONTROLLED STUDY; CYP1A2 GENE; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; GDF15 GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; GREB1 GENE; HUMAN; HUMAN CELL; IGFBP3 GENE; IL8 GENE; IN VITRO STUDY; LCN2 GENE; NCAM2 GENE; NRCAM GENE; PHENOTYPE; PTGS2 GENE; RNA ANALYSIS; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TFF1 GENE; TFF3 GENE; UPREGULATION; BREAST NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PRINCIPAL COMPONENT ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CAVEOLIN 1; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRINCIPAL COMPONENT ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RNA, MESSENGER; SEQUENCE ANALYSIS, RNA; TRASTUZUMAB; UP-REGULATION;

EID: 84923351412     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117818     Document Type: Article

References (99)

1. Roskoski R Jr (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 79:34-74. doi: 10.1016/j.phrs.2013.11.002 PMID: 24269963
2. Heil J, Gondos A, Rauch G, Marmé F, Rom J, et al. (2012) Outcome analysis of patients with primary breast cancer initially treated at a certified academic breast unit. Breast 21(3):303-308. doi: 10.1016/j.breast.2012.01.009 PMID: 22310244
3. Jelovac D, Wolff AC (2012) The adjuvant treatment of HER2-positive breast cancer. Curr Treat Options Oncol 13(2):230-239. doi: 10.1007/s11864-012-0186-4 PMID: 22410709
4. Valabrega G, Montemurro F, Aglietta M (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18(6):977-984. doi: 10.1093/annonc/mdl475 PMID: 17229773
5. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, et al. (2012) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9:16-32. doi: 10.1038/nrclinonc.2011.177
6. O 'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, et al. (2010) Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 9(6):1489-1502. doi: 10.1158/1535-7163.MCT-09-1171 PMID: 20501798
7. Figueroa-Magalhães MC, Jelovac D, Connolly RM, Wolff AC (2014) Treatment of HER2-positive breast cancer. The Breast 23(2):128-136. doi: 10.1016/j.breast.2013.11.011 PMID: 24360619
8. Sherry ST, Ward M, Sirotkin K (1999) dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res 9(8):677-679. PMID: 10447503
9. Brookes AJ (1999) The essence of SNPs. Gene 234(2):177-186. doi: 10.1016/S0378-1119(99)00219-X PMID: 10395891
10. Gray IC, Campbell DA, Spurr NK (2000) Single nucleotide polymorphisms as tools in human genetics. Hum Mol Genet 9(16):2403-2408. doi: 10.1093/hmg/9.16.2403 PMID: 11005795
11. Kwok PY, Chen X (2003) Detection of single nucleotide polymorphisms. Curr Issues Mol Biol 5(2):43-60. PMID: 12793528
12. Quinn EM, Cormican P, Kenny EM, Hill M, Anney R, et al. (2013) Development of strategies for SNP detection in RNA-seq data: Application to lymphoblastoid cell lines and evaluation using 1000 genomes data. PLoS ONE 8(3):e58815. doi: 10.1371/journal.pone.0058815 PMID: 23555596
13. Henjes F, Bender C, von der Heyde S, Braun L, Mannsperger HA, et al. (2012) Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis 1:e16. doi: 10.1038/oncsis.2012.16 PMID: 23552733
14. Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, et al. (2010) Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 21(2):255-262. doi: 10.1093/annonc/mdp304 PMID: 19633047
15. Dodt M, Roehr JT, Ahmed R, Dieterich C (2012) FLEXBAR-Flexible barcode and adapter processing for next-generation sequencing platforms. Biology 1(3):895-905. doi: 10.3390/biology1030895 PMID: 24832523
16. Harrow J, Denoeud F, Frankish A, Reymond A, Chen CK, et al. (2006) GENCODE: producing a reference annotation for ENCODE. Genome Biol 7 Suppl 1:S4.1-9. doi: 10.1186/gb-2006-7-s1-s4 PMID: 16925838
17. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, et al. (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29:15-21. doi: 10.1093/bioinformatics/bts635 PMID: 23104886
18. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, et al. (2009) The sequence alignment/map format and SAMtools. Bioinformatics 25(16):2078-2079. doi: 10.1093/bioinformatics/btp352 PMID: 19505943
19. Anders S, Pyl PT, Huber W (2015) HTSeq - a Python framework to work with high-throughput sequencing data. Bioinformatics 31(2):166-169. doi: 10.1093/bioinformatics/btu638 PMID: 25260700
20. Flicek P, Amode MR, Barrell D, Beal K, Billis K, et al. (2014) Ensembl 2014. Nucleic Acids Res 42(D1): D749-D755. doi: 10.1093/nar/gkt1196 PMID: 24316576
21. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, et al. (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43(5):491-498. doi: 10.1038/ng.806 PMID: 21478889
22. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, et al. (2010) Deriving the consequences of genomic variants with the ensembl API and SNP effect predictor. Bioinformatics 26(16):2069-2070. doi: 10.1093/bioinformatics/btq330 PMID: 20562413
23. Anders S, Huber W (2010) Differential expression analysis for sequence count data. Genome Biol 11 (10):R106. doi: 10.1186/gb-2010-11-10-r106 PMID: 20979621
24. R Core Team (2013) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. R-project website: http://www.R-project.org/ Accessed 2015 Jan 9.
25. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289-300.
26. Durinck S, Spellman PT, Birney E, Huber W (2009) Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc 4(8):1184-1191. doi: 10.1038/nprot.2009.97 PMID: 19617889
27. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402-408. doi: 10.1006/meth.2001.1262 PMID: 11846609
28. Fishman WH (1987) Clinical and biological significance of an isozyme tumor marker-PLAP. Clin Biochem 20(6):387-392. doi: 10.1016/0009-9120(87)90003-8 PMID: 3325192
29. Ayari I, Fedeli U, Saguem S, Hidar S, Khlifi S, et al. (2013) Role of CYP1A2 polymorphisms in breast cancer risk in women. Mol Med Rep 7:280-286. doi: 10.3892/mmr.2012 PMID: 23128882
30. Sekhar SC, Kasai T, Satoh A, Shigehiro T, Mizutani A, et al. (2013) Identification of caveolin-1 as a potential causative factor in the generation of trastuzumab resistance in breast cancer cells. J Cancer 4 (5):391-401. doi: 10.7150/jca.6470 PMID: 23833684
31. Prat A, Bianchini G, Thomas M, Belousov A, Cheang MCU, et al. (2014) Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res 20(2):511-521. doi: 10.1158/1078-0432.CCR-13-0239 PMID: 24443618
32. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, et al. (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. The Lancet 375(9712):377-384. doi: 10.1016/S0140-6736(09)61964-4 PMID: 20113825
33. Knutson TP, Daniel AR, Fan D, Silverstein KA, Covington KR, et al. (2012) Phosphorylated and sumoy-lation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res 14(3):R95. doi: 10.1186/bcr3211 PMID: 22697792
34. Dokmanovic M, Shen Y, Bonacci TM, Hirsch DS, Wu WJ (2011) Trastuzumab regulates IGFBP-2 and IGFBP-3 to mediate growth inhibition: implications for the development of predictive biomarkers for trastuzumab resistance. Mol Cancer Ther 10(6):917-928. doi: 10.1158/1535-7163.MCT-10-0980 PMID: 21487052
35. Jerome L, Alami N, Belanger S, Page V, Yu Q, et al. (2006) Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res 66(14):7245-7252. doi: 10.1158/0008-5472.CAN-05-3555 PMID: 16849573
36. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (herceptin). J Natl Cancer Inst 93(24):1852-1857. doi: 10.1093/jnci/93.24.1852 PMID: 11752009
37. Baggiolini M, Clark-Lewis I (1992) Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 307:97-101. doi: 10.1016/0014-5793(92)80909-Z PMID: 1639201
38. Korkaya H, Kim GI, Davis A, Malik F, Henry NL, et al. (2012) Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 47(4):570-584. doi: 10.1016/j.molcel.2012.06.014 PMID: 22819326
39. Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, et al. (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62(3):632-635. PMID: 11830510
40. Wang SC, Lien HC, Xia W, Chen IF, Lo HW, et al. (2004) Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6(3):251-261. doi: 10.1016/j.ccr.2004.07.012 PMID: 15380516
41. Flowers M, Thompson PA (2009) t10c12 conjugated linoleic acid suppresses HER2 protein and enhances apoptosis in SKBr3 breast cancer cells: possible role of COX2. PLoS ONE 4(4):e5342. doi: 10.1371/journal.pone.0005342 PMID: 19399184
42. Benoit V, Relic B, Leval Xd Xd, Chariot A, Merville MP, et al. (2004) Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene 23(8):1631-1635. doi: 10.1038/sj.onc.1207295 PMID: 14985703
43. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ (2001) Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8(2):97-114. doi: 10.1677/erc.0.0080097 PMID: 11397667
44. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, et al. (1999) Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18(2):305-314. doi: 10.1038/sj.onc.1202307 PMID: 9927187
45. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19(13):3159-3167. doi: 10.1093/emboj/19.13.3159 PMID: 10880430
46. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, et al. (2004) Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2(11):632-642. PMID: 15561779
47. Gianni L (2002) The future of targeted therapy: combining novel agents. Oncology 63 Suppl 1:47-56. doi: 10.1159/000066197 PMID: 12422055
48. Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, et al. (2004) Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastu-zumab-based treatments. Clin Cancer Res 10(12 Pt 1):4062-4067. doi: 10.1158/1078-0432.CCR-03-0463 PMID: 15217939
49. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, et al. (2001) Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120(7):1713-1719. doi: 10.1053/gast.2001.24844 PMID: 11375952
50. Cho HY, Thomas S, Golden EB, Gaffney KJ, Hofman FM, et al. (2009) Enhanced killing of chemoresistant breast cancer cells via controlled aggravation of ER stress. Cancer Lett 282:87-97. doi: 10.1016/j.canlet.2009.03.007 PMID: 19345476
51. Morrison LE, Jewell SS, Usha L, Blondin BA, Rao RD, et al. (2007) Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer. Genes Chromosomes Cancer 46(4):397-405. doi: 10.1002/gcc.20419 PMID: 17243161
52. Joshi JP, Brown NE, Griner SE, Nahta R (2011) Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells. Biochem Pharmacol 82(9):1090-1099. doi: 10.1016/j.bcp.2011.07.082 PMID: 21803025
53. Kumandan S, Mahadevan NR, Chiu K, DeLaney A, Zanetti M (2013) Activation of the unfolded protein response bypasses trastuzumab-mediated inhibition of the PI-3K pathway. Cancer Lett 329(2):236-242. doi: 10.1016/j.canlet.2012.11.014 PMID: 23200669
54. Lin HH, Liao CJ, Lee YC, Hu KH, Meng HW, et al. (2011) Lipocalin-2-induced cytokine production enhances endometrial carcinoma cell survival and migration. Int J Biol Sci 7:74-86. doi: 10.7150/ijbs.7.74 PMID: 21278918
55. Ji Q, Aoyama C, Nien YD, Liu PI, Chen PK, et al. (2004) Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. Cancer Res 64(20):7610-7617. doi: 10.1158/0008-5472.CAN-04-1608 PMID: 15492289
56. Janssen JWG, Cuny M, Orsetti B, Rodriguez C, Vallés H, et al. (2002) MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer. Int J Cancer 102(6):608-614. doi: 10.1002/ijc.10765 PMID: 12448002
57. Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, et al. (2013) Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Cancer 4:36-49. doi: 10.1007/s12672-012-0127-5 PMID: 23184698
58. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, et al. (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203(2):661-671. doi: 10.1002/path.1559 PMID: 15141381
59. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, et al. (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161(6):1991-1996. doi: 10.1016/S0002-9440(10)64476-8 PMID: 12466114
60. Yousef GM, Scorilas A, Kyriakopoulou LG, Rendl L, Diamandis M, et al. (2002) Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. Clin Chem 48(8):1241-1250. PMID: 12142380
61. Luo LY, Diamandis EP, Look MP, Soosaipillai AP, Foekens JA (2002) Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br J Cancer 86(11):1790-1796. doi: 10.1038/sj.bjc.6600323 PMID: 12087468
62. Yousef GM, Yacoub GM, Polymeris ME, Popalis C, Soosaipillai A, et al. (2004) Kallikrein gene downregulation in breast cancer. Br J Cancer 90:167-172. doi: 10.1038/sj.bjc.6601451 PMID: 14710225
63. Li X, Yang Q, Yu H, Wu L, Zhao Y, et al. (2014) LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget 5(3):788-801. PMID: 24553191
64. Agnihotri N, Kumar S, Mehta K (2013) Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer. Breast Cancer Res 15:202. doi: 10.1186/bcr3371 PMID: 23673317
65. Chen PS, Wang MY, Wu SN, Su JL, Hong CC, et al. (2007) CTGF enhances the motility of breast cancer cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway. J Cell Sci 120 (Pt 12):2053-2065. doi: 10.1242/jcs.03460 PMID: 17550972
66. Gonc¸alves A, Charafe-Jauffret E, Bertucci F, Audebert S, Toiron Y, et al. (2008) Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics 7(8):1420-1433. doi: 10.1074/mcp.M700487-MCP200 PMID: 18426791
67. Verma P, Ostermeyer-Fay AG, Brown DA (2010) Caveolin-1 induces formation of membrane tubules that sense actomyosin tension and are inhibited by polymerase I and transcript release factor/cavin-1. Mol Biol Cell 21(13):2226-2240. doi: 10.1091/mbc.E09-05-0417 PMID: 20427576
68. Di Cello F, Cope L, Li H, Jeschke J, Wang W, et al. (2013) Methylation of the claudin 1 promoter is associated with loss of expression in estrogen receptor positive breast cancer. PLoS ONE 8(7):e68630. doi: 10.1371/journal.pone.0068630 PMID: 23844228
69. Lu S, Singh K, Mangray S, Tavares R, Noble L, et al. (2013) Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype. Mod Pathol 26(4):485-495. doi: 10.1038/modpathol.2012.187 PMID: 23222490
70. Lee YK, Lee SY, Park JR, Kim RJ, Kim SR, et al. (2012) Dysadherin expression promotes the motility and survival of human breast cancer cells by AKT activation. Cancer Sci 103(7):1280-1289. doi: 10.1111/j.1349-7006.2012.02302.x PMID: 22494103
71. Zhao C, Putnik M, Gustafsson JA, Dahlman-Wright K (2009) Microarray analysis of altered gene expression in ERbeta-overexpressing HEK293 cells. Endocrine 36(2):224-232. doi: 10.1007/s12020-009-9233-8 PMID: 19680825
72. Ahmed ARH, Griffiths AB, Tilby MT, Westley BR, May FEB (2012) TFF3 is a normal breast epithelial protein and is associated with differentiated phenotype in early breast cancer but predisposes to invasion and metastasis in advanced disease. Am J Pathol 180(3):904-916. doi: 10.1016/j.ajpath.2011.11.022 PMID: 22341453
73. Doane AS, Danso M, Lal P, Donaton M, Zhang L, et al. (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25(28):3994-4008. doi: 10.1038/sj.onc.1209415 PMID: 16491124
74. Lacroix M (2006) Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 13(4):1033-1067. doi: 10.1677/ERC-06-0001 PMID: 17158753
75. Yu JC, Hsiung CN, Hsu HM, Bao BY, Chen ST, et al. (2011) Genetic variation in the genome-wide predicted estrogen response element-related sequences is associated with breast cancer development. Breast Cancer Res 13:R13. doi: 10.1186/bcr2821 PMID: 21281495
76. Srinivasan S, Nwachukwu JC, Parent AA, Cavett V, Nowak J, et al. (2013) Ligand-binding dynamics rewire cellular signaling via estrogen receptor-α. Nat Chem Biol 9(5):326-332. doi: 10.1038/nchembio.1214 PMID: 23524984
77. Liu M, Wang G, Gomez-Fernandez CR, Guo S (2012) GREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancer. PLoS ONE 7(10):e46410. doi: 10.1371/journal.pone.0046410 PMID: 23056300
78. Evans AH, Pancholi S, Farmer I, Thornhill A, Evans DB, et al. (2010) EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy. Br J Cancer 102(8):1235-1243. doi: 10.1038/sj.bjc.6605641 PMID: 20386540
79. Collins DC, Cocchiglia S, Tibbitts P, Solon G, Bane FT, et al. (2014) Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer. Oncogene [Epub ahead of print] doi: 10.1038/onc.2013.586
80. Einarsdóttir K, Rosenberg LU, Humphreys K, Bonnard C, Palmgren J, et al. (2006) Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study. Breast Cancer Res 8(6):R67. doi: 10.1186/bcr1623 PMID: 17132159
81. Benusiglio PR, Lesueur F, Luccarini C, Conroy DM, Shah M, et al. (2005) Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. Breast Cancer Res 7(2):R204-209. doi: 10.1186/bcr982 PMID: 15743501
82. Breyer JP, Sanders ME, Airey DC, Cai Q, Yaspan BL, et al. (2009) Heritable variation of ERBB2 and breast cancer risk. Cancer Epidemiol Biomarkers Prev 18(4):1252-1258. doi: 10.1158/1055-9965.EPI-08-1202 PMID: 19336545
83. Festa-Vasconcellos JS, Piranda DN, Amaral LM, Indio-do Brasil V, Koifman S, et al. (2012) Polymorphisms in cycloxygenase-2 gene and breast cancer prognosis: association between PTGS2 haplotypes and histopathological features. Breast Cancer Res Treat 132:251-258. doi: 10.1007/s10549-011-1828-0 PMID: 22037828
84. Gerger A, Renner W, Langsenlehner T, Hofmann G, Knechtel G, et al. (2010) Association of interleu-kin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat 119(3):701-705. doi: 10.1007/s10549-009-0417-y PMID: 19437115
85. Abraham JE, Harrington P, Driver KE, Tyrer J, Easton DF, et al. (2009) Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clin Cancer Res 15(6):2181-2191. doi: 10.1158/1078-0432.CCR-08-0716 PMID: 19276290
86. Yu KD, Chen AX, Yang C, Qiu LX, Fan L, et al. (2010) Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 122:251-257. doi: 10.1007/s10549-010-0738-x PMID: 20033767
87. Zhu W, Wei Bb, Shan X, Liu P (2010) -765G>C and 8473T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep 37:277-288. doi: 10.1007/s11033-009-9685-1 PMID: 19669667
88. Moore AE, Young LE, Dixon DA (2012) A common single-nucleotide polymorphism in cyclooxygenase-2 disrupts microRNA-mediated regulation. Oncogene 31(12):1592-1598. doi: 10.1038/onc.2011.349 PMID: 21822307
89. Jung JH, Chae YS, Moon JH, Kang BW, Kim JG, et al. (2010) TNF superfamily gene polymorphism as prognostic factor in early breast cancer. J Cancer Res Clin Oncol 136(5):685-694. doi: 10.1007/s00432-009-0707-0 PMID: 19890662
90. Cox DG, Buring J, Hankinson SE, Hunter DJ (2007) A polymorphism in the 3′ untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Res 9:R3. doi: 10.1186/bcr1635 PMID: 17214885
91. Qian B, Zheng H, Yu H, Chen K (2011) Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women. Breast Cancer Res Treat 130:217-226. doi: 10.1007/s10549-011-1552-9 PMID: 21562710
92. Su X, Colditz GA, Willett WC, Collins LC, Schnitt SJ, et al. (2010) Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. Int J Cancer 126:180-190. doi: 10.1002/ijc.24674 PMID: 19551864
93. D'Aloisio AA, Schroeder JC, North KE, Poole C, West SL, et al. (2009) IGF-I and IGFBP-3 polymorphisms in relation to circulating levels among African American and Caucasian women. Cancer Epidemiol Biomarkers Prev 18(3):954-966. doi: 10.1158/1055-9965.EPI-08-0856 PMID: 19240240
94. Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, et al. (2008) IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the breast and prostate cancer cohort consortium (BPC3). PLoS ONE 3(7):e2578. doi: 10.1371/journal.pone.0002578 PMID: 18596909
95. Cheng I, DeLellis Henderson K, Haiman CA, Kolonel LN, Henderson BE, et al. (2007) Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. J Clin Endocrinol Metab 92(9):3660-3666. doi: 10.1210/jc.2007-0790 PMID: 17566087
96. Tamimi RM, Cox DG, Kraft P, Pollak MN, Haiman CA, et al. (2007) Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res 9:R18. doi: 10.1186/bcr1655 PMID: 17300730
97. Tong L, Yang XX, Liu MF, Yao GY, Dong JY, et al. (2012) Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients. Asian Pac J Cancer Prev 13(11):5599-5603. doi: 10.7314/APJCP.2012.13.11.5599 PMID: 23317280
98. Gray KA, Daugherty LC, Gordon SM, Seal RL, Wright MW, et al. (2013) Genenames.org: the HGNC resources in 2013. Nucleic Acids Res 41(Database issue):D545-552. doi: 10.1093/nar/gks1066 PMID: 23161694
99. Maglott D, Ostell J, Pruitt KD, Tatusova T (2005) Entrez gene: gene-centered information at NCBI. Nucleic Acids Res 33(Database issue):D54-58. doi: 10.1093/nar/gki031 PMID: 15608257